ARTICLE
2 February 2015

Top 10 Most Read Health Law Update Blog Posts In 2014

B
BakerHostetler

Contributor

BakerHostetler logo
Recognized as one of the top firms for client service, BakerHostetler is a leading national law firm that helps clients around the world address their most complex and critical business and regulatory issues. With five core national practice groups — Business, Labor and Employment, Intellectual Property, Litigation, and Tax — the firm has more than 970 lawyers located in 14 offices coast to coast. BakerHostetler is widely regarded as having one of the country’s top 10 tax practices, a nationally recognized litigation practice, an award-winning data privacy practice and an industry-leading business practice. The firm is also recognized internationally for its groundbreaking work recovering more than $13 billion in the Madoff Recovery Initiative, representing the SIPA Trustee for the liquidation of Bernard L. Madoff Investment Securities LLC. Visit bakerlaw.com
BakerHostetler launched the Health Law Update blog in 2014 as an enhancement of the Health Law Update newsletter.
United States Food, Drugs, Healthcare, Life Sciences

BakerHostetler launched the Health Law Update blog in 2014 as an enhancement of the Health Law Update newsletter. To commemorate this first anniversary, we've compiled a list of the top 10 popular posts from the blog's inaugural year.

  1. There's a Code for That: Counting Down to ICD-10 and a Poem to Help You Remember!
  2. OIG Issues Special Advisory Bulletin Covering Manufacturer Copay Coupons and Medicare Part D
  3. FDA Regulation of Compounding Pharmacies: Unsolved Mysteries
  4. Obligations During the Ebola Crisis: Ethical and Practical Considerations
  5. Government Sues Hospital for Birthing Mama's Babies
  6. Get Ready! HHS OCR Announces Next Round of HIPAA Audits
  7. Implications on Pharmacies of Recent OIG Advisory Opinion on Per-Fill Fees
  8. Ebola Information Quarantine: Balancing Patient Privacy With Public Health
  9. The Orphan Drug Wars: HHS's Rebuttal to Its Recent Loss to PhRMA
  10. FDA Regulation of Laboratory Developed Tests on the Horizon

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More